RB1 and cancer: In MCPyV-positive cancers, sustained tumor growth is contingent on the presence of a functional large T antigen with intact RB1 binding domain to sequester and inactivate the tumor suppressor, which may serve as an important therapeutic target for the subset of MCPyV-positive cancers [23,24].